RESUMEN
The discovery that several drug hypersensitivity reactions (DHRs) are associated with specific human leukocyte antigen (HLA) alleles has attracted increasing research interest. However, the underlying mechanisms of these HLA-induced DHRs remain unclear, especially for drug-induced immediate activation of T-cell clones (TCCs). Recently, a novel hypothesis involving partial detachment between self-peptide(s) and the HLA molecule (altered peptide-HLA (pHLA) model) has been proposed to explain these phenomena. In order to clarify this hypothesis, we performed long-timescale molecular dynamics (MD) simulations. We focused on HLA-Bâ57:01-restricted abacavir hypersensitivity reactions (AHRs), one of the most famous DHRs. One of the simulation results showed that this altered-pHLA model might be driven by an increase in the distance not only between HLA and self-peptides but also between the α1 and α2 helices of HLA. Our findings provide novel insights into abacavir-induced immediate activation of TCCs and these findings might also be applied to other DHRs, such as HLA-Bâ58:01-restricted allopurinol hypersensitivity reactions.
RESUMEN
BACKGROUND: Thalidomide and its analogs, lenalidomide and pomalidomide (referred to as immunomodulatory imide drugs or IMiDs) have been known to treat multiple myeloma and other hematologic malignancies as well as to cause teratogenicity. Recently the protein cereblon was identified as the primary target of IMiDs, and crystallographic studies of the cereblon-IMiDs complex showed strong enantioselective binding for the (S)-enantiomer of IMiDs. RESULTS: Using the structures of cereblon and IMiDs [both (S)-enantiomers and (R)-enantiomers] we performed docking simulations in order to replicate this enantiomeric selectivity and to identify the region(s) contributing to this selectivity. We confirmed the enantioselective binding of IMiDs to cereblon with high accuracy, and propose that the hairpin connecting the ß10-ß11 region of cereblon (residues 351-355) contributes to this selectivity and to the increased affinity with IMiDs. CONCLUSIONS: Our docking results provide novel insights into the binding mode of IMiD-like molecules and contribute to a deeper understanding of cereblon-related biology.
RESUMEN
1. The biotransformation and disposition of tivantinib in humans, dogs and rats was examined after a single oral administration of [(14)C]tivantinib. Tivantinib constituted no more than one-third of the plasma radioactivity in all species, demonstrating significant contribution of the metabolites to plasma radioactivity. The major circulating metabolites in all species were M4 and M5, hydroxylated metabolites at the benzyl position of the tricyclic ring, accounting for 19.3 and 12.2% of the AUC of the total radioactivity, respectively, in humans. 2. The majority of radioactivity was excreted to the feces via bile. Tivantinib was detected at trace levels in urine, feces and bile, demonstrating extensive metabolism prior to biliary excretion and nearly complete tivantinib absorption under fed conditions. 3. Seven metabolic pathways were identified for tivantinib and included six oxidations (M4, M5, M7, M8, M9 and M11) and one glucuronidation (M23). The major metabolic and excretory pathways were found to be common among all species. Species differences in the metabolic pathways included lactam metabolite (M8) formation in humans and dehydrogenated metabolite (M11) formation in animals. 4. None of the metabolites identified in this work are believed to significantly impact the efficacy or toxicity of tivantinib in humans.
Asunto(s)
Pirrolidinonas/metabolismo , Pirrolidinonas/farmacocinética , Quinolinas/metabolismo , Quinolinas/farmacocinética , Administración Oral , Adolescente , Adulto , Animales , Bilis , Biotransformación , Radioisótopos de Carbono/análisis , Línea Celular Tumoral , Niño , Perros , Heces , Humanos , Hidroxilación , Masculino , Redes y Vías Metabólicas , Metaboloma , Persona de Mediana Edad , Ratas , Ratas Sprague-Dawley , Orina , Adulto JovenRESUMEN
(2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl 4-O-(6-deoxy-ß-D-glucopyranosyl)-α-D-glucopyranoside (CS-1036) is a potent inhibitor of pancreatic and salivary α-amylase. After oral administration of [¹4C]CS-1036 to rats, the radioactivity was still detectable up to 7-14 days after administration in various tissues, and its terminal phase in plasma could be explained neither by the exposure of CS-1036 nor its major metabolite M1. The slow elimination of radioactivity in various tissues was hypothesized to be caused by covalent binding to macromolecules or use for biogenic components. To assess the use for biogenic components, amino acid analysis of plasma proteins and lipid analysis of adipose tissue were conducted after repeated oral administration of [¹4C]CS-1036 by high-performance liquid chromatography and accelerated mass spectrometry and by thin layer chromatography and liquid chromatography/mass spectrometry, respectively. In amino acid analysis, glutamic acid, aspartic acid, alanine, and proline were identified as major radioactive amino acids, and radioactive nonessential amino acids occupied 76.0% of the radioactivity. In lipid analysis, a part of the radioactive lipids were identified as the fatty acids constituting the neutral lipids by lipase-hydrolysis. The radioactive fatty acids from neutral lipids were identified as palmitic acid, oleic acid, and 8,11,14-eicosatrienoic acid. Intestinal flora were involved in CS-1036 metabolism and are indicated to be involved in the production of small molecule metabolites, which are the sources for amino acids and fatty acids, from [¹4C]CS-1036. In conclusion, radioactivity derived from [¹4C]CS-1036 was incorporated as the constituents of amino acids of plasma proteins and fatty acids of neutral lipids.
Asunto(s)
Disacáridos/farmacocinética , Inhibidores Enzimáticos/farmacocinética , Pirrolidinas/farmacocinética , alfa-Amilasas/antagonistas & inhibidores , Administración Oral , Aminoácidos/sangre , Animales , Cromatografía Líquida de Alta Presión , Cromatografía en Capa Delgada , Disacáridos/administración & dosificación , Disacáridos/farmacología , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Ácidos Grasos/sangre , Hidrólisis , Masculino , Pirrolidinas/administración & dosificación , Pirrolidinas/farmacología , Radiometría , Ratas , Ratas Endogámicas F344 , Distribución TisularRESUMEN
The absorption, metabolism, and excretion of (2R,3R,4R)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-3-yl 4-O-(6-deoxy-ß-d-glucopyranosyl)-α-d-glucopyranoside (CS-1036), a novel and potent pancreatic and salivary α-amylase inhibitor, were evaluated in F344/DuCrlCrlj rats and cynomolgus monkeys. The total body clearance and volume of distribution of CS-1036 were low (2.67-3.44 ml/min/kg and 0.218-0.237 l/kg for rats and 2.25-2.84 ml/min/kg and 0.217-0.271 l/kg for monkeys). After intravenous administration of [(14)C]CS-1036 to rats and monkeys, radioactivity was mainly excreted into urine (77.2% for rats and 81.1% for monkeys). After oral administration, most of the radioactivity was recovered from feces (80.28% for rats and 88.13% for monkeys) with a low oral bioavailability (1.73-2.44% for rats and 0.983-1.20% for monkeys). In rats, intestinal secretion is suggested to be involved in the fecal excretion as a minor component because fecal excretion after intravenous administration was observed (15.66%) and biliary excretion was almost negligible. Although intestinal flora was involved in CS-1036 metabolism, CS-1036 was the main component in feces (70.3% for rats and 48.7% for monkeys) and in the intestinal contents (33-68% for rats up to 2 hours after the dose) after oral administration. In Zucker diabetic fatty rats, CS-1036 showed a suppressive effect on plasma glucose elevation after starch loading with a 50% effective dose at 0.015 mg/kg. In summary, CS-1036 showed optimal pharmacokinetic profiles: low oral absorption and favorable stability in gastrointestinal lumen, resulting in suppression of postprandial hyperglycemia by α-amylase inhibition.
Asunto(s)
Glucemia/efectos de los fármacos , Disacáridos/farmacocinética , Absorción Intestinal/efectos de los fármacos , Pirrolidinas/farmacocinética , alfa-Amilasas/antagonistas & inhibidores , Absorción , Administración Oral , Animales , Disponibilidad Biológica , Disacáridos/administración & dosificación , Disacáridos/farmacología , Inyecciones Intravenosas , Macaca fascicularis , Masculino , Pirrolidinas/administración & dosificación , Pirrolidinas/farmacología , Ratas , Distribución TisularRESUMEN
Asthma is one of the most prevalent diseases in the world, for which the mainstay treatment has been inhaled glucocorticoids (GCs). Despite the widespread use of these drugs, approximately 30% of asthma sufferers exhibit some degree of steroid insensitivity or are refractory to inhaled GCs. One hypothesis to explain this phenomenon is interpatient variability in the clearance of these compounds. The objective of this research is to determine how metabolism of GCs by the CYP3A family of enzymes could affect their effectiveness in asthmatic patients. In this work, the metabolism of four frequently prescribed inhaled GCs, triamcinolone acetonide, flunisolide, budesonide, and fluticasone propionate, by the CYP3A family of enzymes was studied to identify differences in their rates of clearance and to identify their metabolites. Both interenzyme and interdrug variability in rates of metabolism and metabolic fate were observed. CYP3A4 was the most efficient metabolic catalyst for all the compounds, and CYP3A7 had the slowest rates. CYP3A5, which is particularly relevant to GC metabolism in the lungs, was also shown to efficiently metabolize triamcinolone acetonide, budesonide, and fluticasone propionate. In contrast, flunisolide was only metabolized via CYP3A4, with no significant turnover by CYP3A5 or CYP3A7. Common metabolites included 6ß-hydroxylation and Δ(6)-dehydrogenation for triamcinolone acetonide, budesonide, and flunisolide. The structure of Δ(6)-flunisolide was unambiguously established by NMR analysis. Metabolism also occurred on the D-ring substituents, including the 21-carboxy metabolites for triamcinolone acetonide and flunisolide. The novel metabolite 21-nortriamcinolone acetonide was also identified by liquid chromatography-mass spectrometry and NMR analysis.
Asunto(s)
Antiasmáticos/administración & dosificación , Antiasmáticos/metabolismo , Citocromo P-450 CYP3A/metabolismo , Glucocorticoides/administración & dosificación , Glucocorticoides/metabolismo , Pulmón/enzimología , Administración por Inhalación , Androstadienos/administración & dosificación , Androstadienos/metabolismo , Antiasmáticos/química , Hidrocarburo de Aril Hidroxilasas/metabolismo , Biotransformación , Budesonida/administración & dosificación , Budesonida/metabolismo , Catálisis , Cromatografía Líquida de Alta Presión , Fluocinolona Acetonida/administración & dosificación , Fluocinolona Acetonida/análogos & derivados , Fluocinolona Acetonida/metabolismo , Fluticasona , Glucocorticoides/química , Humanos , Hidroxilación , Isoenzimas , Cinética , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Estructura Molecular , Proteínas Recombinantes/metabolismo , Triamcinolona Acetonida/administración & dosificación , Triamcinolona Acetonida/metabolismoRESUMEN
Inhaled glucocorticoid (GC) therapy is a vital part of the management of chronic asthma. GCs are metabolized by members of the cytochrome P450 3A family in both liver and lung, but the enzymes are differentially expressed. Selective inhibition of one or more P450 3A enzymes could substantially modify target and systemic concentrations of GCs. In this study, we have evaluated the mechanism-based inactivation of P450 3A4, 3A5, and 3A7 enzymes by GCs. Among the five major inhaled GCs approved for clinical use in the United States, fluticasone propionate (FLT) was the most potent mechanism-based inactivator of P450 3A5, the predominant P450 enzyme in the lung. FLT inactivated P450 3A5 in a time- and concentration-dependent manner with K(I), k(inact), and partition ratio of 16 muM, 0.027 min(-1), and 3, respectively. In contrast, FLT minimally inactivated P450 3A4 and did not inactivate 3A7, even with a concentration of 100 muM. The inactivation of P450 3A5 by FLT was irreversible because dialysis did not restore enzyme activity. In addition, the exogenous nucleophilic scavenger GSH did not attenuate inactivation. The prosthetic heme of P450 3A5 was not modified by FLT. The loss of P450 3A5 activity in lung cells could substantially decrease the metabolism of FLT, which would increase the effective FLT concentration at its target site, the respiratory epithelium. Also, inactivation of lung P450 3A5 could increase the absorption of inhaled FLT, which could lead to high systemic concentrations and adverse effects, such as life-threatening adrenal crises or cataracts that have been documented in children receiving high doses of inhaled GCs.
Asunto(s)
Androstadienos/administración & dosificación , Androstadienos/farmacología , Inhibidores del Citocromo P-450 CYP3A , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/farmacología , Glucocorticoides/farmacología , Pulmón/enzimología , Administración por Inhalación , Androstadienos/toxicidad , Antialérgicos/administración & dosificación , Antialérgicos/farmacología , Antialérgicos/toxicidad , Citocromo P-450 CYP3A , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/toxicidad , Fluticasona , Glucocorticoides/administración & dosificación , Glucocorticoides/toxicidad , Humanos , Pulmón/citología , Proteínas Recombinantes/antagonistas & inhibidores , Relación Estructura-Actividad , Factores de TiempoRESUMEN
Acyl glucuronides (AGs) formed from carboxylic acid-containing drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT). Chemical stability of AGs is supposed to relate to their reactivity. In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) solution, and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs. The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk. As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA solution or in human fresh plasma with regard to the separation of the safe drugs from the warning drugs or the withdrawn drugs. In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter. The classification value of the half-life in KPB, which separated the safe drugs from the withdrawn drugs was calculated to be 3.6 h by regression analysis. In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chemical stability of AGs in several in vitro systems. The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacocinética , Ácidos Carboxílicos/química , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Glucurónidos/metabolismo , Preparaciones Farmacéuticas/metabolismo , Acilación , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/clasificación , Antiinflamatorios no Esteroideos/toxicidad , Tampones (Química) , Glucurónidos/sangre , Semivida , Humanos , Modelos Logísticos , Estructura Molecular , Preparaciones Farmacéuticas/sangre , Preparaciones Farmacéuticas/química , Preparaciones Farmacéuticas/clasificación , Valor Predictivo de las Pruebas , Albúmina Sérica/químicaRESUMEN
In the course of experiments to perform deprotonation and carbonization of doped polyaniline (PANI) nanotubes (NTs) by irradiating directly 2.45 GHz microwave (MW) in our microwave heating system (MWHS), we have discovered that the PANI-NTs self heat by absorbing the MW but the temperature of the PANI-NTs stops rising around 300 degrees C in spite of the heightened MW power Furthermore, we have found that the MW irradiated PANI-NTs have transferred from electrical conductor to insulator depending on the temperature of the PANI-NTs. By measuring electron spin resonance (ESR) spectra of the MW heated PANI-NTs, the existence of the unpaired electrons is shown to have a strong correlation between the degree of MW absorption and the transition in the electrical conductivities. In order to deprotonate and carbonize further the PANI-NTs, we have performed heat treatment for the PANI-NTs up to a temperature (T(HT)) of about 1200 degrees C in the same MWHS using carbon fiber which self heats by absorbing MW. The chemical transformations in the PANI-NTs induced by the heat treatments are discussed by measuring the X-ray photoelectron spectroscopy (XPS) spectra. Finally, the temperature dependence of electrical conductivities of the PANI-NTs are measured in order to investigate the mechanism of electrical conduction of the heat treated PANI-NTs.
RESUMEN
Diglucuronidation is a novel glucuronidation reaction where the second glucuronosyl moiety is attached at the C2' position of the first glucuronosyl moiety. To examine whether diglucuronidation takes place in endogenous substrates in vivo, control urine and bile samples were collected from male Crl:CD(SD) IGS rats, beagle dogs, and cynomolgus monkeys and analyzed by liquid chromatography-mass spectrometry (LC-MS) after solid phase extraction. Several diglucuronides of C(19) steroids, including M1 (C(31)H(46)O(14)) and M2 (C(31)H(44)O(14)), were detected in the urine and bile of the dogs but not in the excreta of the rats and monkeys. A milligram quantity of M1 was successfully isolated from the pooled dog urine and analyzed by nuclear magnetic resonance (NMR) spectroscopy. M1 was unambiguously identified as epiandrosterone 3-O-diglucuronide by comparing the LC-MS and two-dimensional NMR data of M1 with those of the biosynthesized epiandrosterone 3-O-diglucuronide. M2 was identified as dehydroepiandrosterone 3-O-diglucuronide. According to these findings, the diglucuronidation reaction was proven to be occurring on steroid hormones in vivo in dogs.
Asunto(s)
Glucurónidos/metabolismo , Congéneres de la Testosterona/metabolismo , Animales , Bilis/química , Perros , Glucurónidos/orina , Humanos , Macaca fascicularis , Masculino , Microsomas Hepáticos/metabolismo , Ratas , Ratas Endogámicas , Extracción en Fase SólidaRESUMEN
Pactimibe sulfate is a novel acyl coenzyme A:cholesterol acyltransferase inhibitor. We conducted metabolic studies of pactimibe and its plasma metabolite, R-125528. Pactimibe had multiple metabolic pathways including indolin oxidation to form R-125528, omega-1 oxidation, N-dealkylation, and glucuronidation. Among them, the indolin oxidation and the omega-1 oxidation were dominant and were mainly catalyzed by CYP3A4 and CYP2D6, respectively. The intrinsic clearance (CL(int)) values for these pathways in human hepatic microsomes were 0.63 and 0.76 microl/min/mg-protein, respectively. On the other hand, the metabolic reaction for R-125528 was restricted. It was demonstrated that omega-1 oxidation was the only pathway that could eliminate R-125528 from the systemic circulation. To our surprise, only CYP2D6-expressing microsomes could catalyze the reaction, and omega-1 oxidation was strongly correlated with the CYP2D6 marker reaction, dextromethorphan O-demethylation (r(2) = 0.90), in human hepatic microsomes. Although R-125528 is an atypical substrate for CYP2D6 because of its acidity, the K(m) value was 1.8 microM for the reaction in human hepatic microsomes and the CL(int) value was as high as 75.0 microl/min/mg-protein. These results suggested that the systemic clearance of R-125528 was highly dependent on CYP2D6 activity and that several studies with CYP2D6 including drug-drug interaction and polymorphism sensitivity should be performed during development from the viewpoint of metabolite safety assessment. The finding that R-125528, an acidic compound devoid of basic nitrogen, was a good substrate for CYP2D6 raised a question about previously reported CYP2D6 models based on a critical electrostatic interaction with Asp(301) and/or Glu(216).
Asunto(s)
Citocromo P-450 CYP2D6/metabolismo , Ácidos Indolacéticos/metabolismo , Esterol O-Aciltransferasa/antagonistas & inhibidores , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacocinética , Humanos , Ácidos Indolacéticos/farmacocinética , Cinética , Linfocitos/enzimología , Microsomas Hepáticos/enzimología , Microsomas Hepáticos/metabolismoRESUMEN
In rats, it has been reported that rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, reacts with the aldehyde group of allysine in elastin to give a condensation covalent adduct, thereby preventing the formation of cross-linkages in the elastin and causing degradation of the elastic fibers in aortas in vivo. Acid, organic solvent, and proteolytic enzyme treatments of human aortic homogenate after incubation with [(14)C]rofecoxib demonstrated that most of the radioactivity is covalently bound to elastin. The in vitro covalent binding was inhibited in the presence of beta-aminopropionitrile, D-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding. The in vitro covalent binding of [(14)C]rofecoxib was significantly decreased by the addition of only nonradiolabeled rofecoxib but not the other COX-2 inhibitors, celecoxib, valdecoxib, etoricoxib, and CS-706 [2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole], a novel selective COX-2 inhibitor. All the above COX-2 inhibitors except for rofecoxib had no reactivity with the aldehyde group of benzaldehyde used as a model compound of allysine aldehyde under a physiological pH condition. On the other hand, no retention of the radioactivity of [(14)C]rofecoxib was observed in human aortic endothelial cells in vitro, suggesting that rofecoxib is not retained in aortic endothelial cells in vivo. These results suggest that rofecoxib, but not other COX-2 inhibitors, is capable of covalently binding to the aldehyde group of allysine in human elastin. This might be one of the main causes of cardiovascular events by rofecoxib in clinical situations.
Asunto(s)
Ácido 2-Aminoadípico/análogos & derivados , Aldehídos/metabolismo , Inhibidores de la Ciclooxigenasa 2/metabolismo , Elastina/metabolismo , Lactonas/metabolismo , Sulfonas/metabolismo , Ácido 2-Aminoadípico/metabolismo , Anciano , Animales , Aorta Abdominal/metabolismo , Aorta Torácica/metabolismo , Línea Celular , Femenino , Humanos , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
We have previously reported that oral administration of [(14)C]rofecoxib to rats resulted in the long retention of radioactivity by the aorta as a consequence of covalent binding to elastin. Treatment of rats with alpha-phenyl-alpha-propylbenzeneacetic acid 2-[diethylamino]-ethyl ester hydrochloride (SKF-525A), a cytochrome P450 inhibitor, significantly decreased the systemic exposure of 5-hydroxyrofecoxib, one of the main metabolites of rofecoxib, whereas there was no statistically significant change in the retention of radioactivity from [(14)C]rofecoxib in the aorta. On the other hand, the aortic retention of radioactivity closely correlated to the systemic exposure of unchanged rofecoxib in the dose range between 2 and 10 mg/kg. A covalent binding study of [(14)C]rofecoxib in vitro using rat aorta homogenate in the presence of d-penicillamine, hydralazine, beta-aminopropionitrile, and sodium borohydride suggested that the aldehyde group of allysine in elastin was relevant to the covalent binding. In a model reaction using benzaldehyde, rofecoxib but not 5-hydroxyrofecoxib reacted with the aldehyde group of benzaldehyde in a manner of condensation reaction under a physiological pH condition. A histopathological examination using an electron microscope demonstrated that multiple oral administration of rofecoxib to rats caused marked degradation of the elastic fiber system of the aorta. These results suggested that rofecoxib as such is reactive in vivo, undergoing a condensation reaction with allysine, thereby preventing the formation of cross-linkages in elastin, i.e., desmosine and isodesmosine, and causing the degradation of the elastic fibers.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Aorta Torácica/efectos de los fármacos , Elastina/metabolismo , Lactonas/farmacología , Sulfonas/farmacología , Animales , Antiinflamatorios no Esteroideos/sangre , Antiinflamatorios no Esteroideos/farmacocinética , Aorta Torácica/metabolismo , Aorta Torácica/ultraestructura , Cromatografía Líquida de Alta Presión , Técnicas In Vitro , Lactonas/sangre , Lactonas/farmacocinética , Masculino , Microscopía Electrónica de Transmisión , Estructura Molecular , Unión Proteica , Ensayo de Unión Radioligante , Ratas , Ratas Sprague-Dawley , Sulfonas/sangre , Sulfonas/farmacocinética , Espectrometría de Masas en TándemRESUMEN
We identified human UDP-glucuronosyltransferase (UGT) isoforms responsible for producing dihydrotestosterone (DHT) diglucuronide, a novel glucuronide in which the second glucuronosyl moiety is attached at the C2' position of the first glucuronosyl moiety, leading to diglucuronosyl conjugation of a single hydroxyl group of DHT at the C17 position. Incubation of the DHT monoglucuronide with 12 cDNA-expressed recombinant human UGT isoforms and uridine 5'-diphosphoglucuronic acid resulted in a low but measurable DHT diglucuronidation activity primarily with UGT1A8, a gastrointestinal UGT, and to a lesser extent with UGT1A1 and UGT1A9. In contrast, the activity of DHT monoglucuronidation was high and was found in UGT2B17, UGT2B15, UGT1A8, and UGT1A4 in descending order. Among the 12 UGT isoforms tested, only UGT1A8 was capable of producing DHT diglucuronide from DHT. The kinetics of DHT diglucuronidation by microsomes from human liver and intestine fitted the Michaelis-Menten model, and the V(max)/K(m) value for the intestinal microsomes was approximately 4 times greater than that for the liver microsomes.
Asunto(s)
Dihidrotestosterona/análogos & derivados , Glucuronosiltransferasa/metabolismo , Animales , Dihidrotestosterona/química , Dihidrotestosterona/metabolismo , Perros , Glucuronosiltransferasa/genética , Humanos , Técnicas In Vitro , Intestinos/enzimología , Isoenzimas/genética , Isoenzimas/metabolismo , Cinética , Microsomas Hepáticos/enzimología , Estructura Molecular , Ratas , Proteínas Recombinantes/metabolismo , UDP Glucuronosiltransferasa 1A9RESUMEN
Androgens (androsterone, dihydrotestosterone and testosterone) and estrogens (estradiol, estriol and estrone) were incubated with liver microsomes from rats, dogs, monkeys and humans in the presence of uridine diphosphoglucuronic acid (UDPGA), and the glucuronides produced were structurally characterized by liquid chromatography-tandem mass spectrometry. After 2-h incubation with dog liver microsomes, all substrates tested were converted (approximately 2-10%) to structurally novel diglucuronides, where two glucuronosyl groups are bound to a single hydroxyl group in tandem. Two-dimensional nuclear magnetic resonance spectroscopy unambiguously elucidated the chemical structures of the 3-O-diglucuronide of estrone and the 17-O-diglucuronide of testosterone isolated from the incubation mixture. Monkey and human liver microsomes were also found to have the activity to form this type of diglucuronide, albeit more slowly than the dog liver microsomes, but rat liver microsomes produced no detectable diglucuronides. The rate of formation of estrone 3-O-diglucuronide from the corresponding monoglucuronide in dog liver microsomes followed classical Michaelis-Menten kinetics at substrate concentrations from 50 to 1000 microM, with a K(m) value of 127.1 microM and a V(max) value of 47.0 pmol/min/mg protein.
Asunto(s)
Glucurónidos/biosíntesis , Glucuronosiltransferasa/metabolismo , Hormonas Esteroides Gonadales/metabolismo , Microsomas Hepáticos/metabolismo , Animales , Cromatografía Liquida , Perros , Estrona/química , Estrona/metabolismo , Glucurónidos/química , Glucurónidos/metabolismo , Hormonas Esteroides Gonadales/química , Haplorrinos , Humanos , Cinética , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Microsomas Hepáticos/enzimología , Ratas , Especificidad de la Especie , Testosterona/química , Testosterona/metabolismo , Uridina Difosfato Ácido GlucurónicoRESUMEN
Incubation of 4-hydroxybiphenyl (p-phenylphenol) in the presence of UDP-glucuronic acid (UDPGA) with liver microsomes from male and female dogs produced a more polar metabolite peak than a simultaneously produced peak of 4-hydroxybiphenyl monoglucuronide in the high performance liquid chromatography (HPLC) chromatogram. Tandem mass spectrometry (MS/MS) and two-dimensional nuclear magnetic resonance (NMR) analyses revealed this polar metabolite as a 4-hydroxybiphenyl diglucuronide having a beta-D-glucuronopyranosyl-(1-->2)-beta-D-glucuronopyranosyl moiety, where the two glucuronic acids are connected directly at the 1''-->2' position. Liver microsomes from Sprague-Dawley rat, cynomolgus monkey and human, converted 4-hydroxybiphenyl only to the monoglucuronide, suggesting that there is a dog UDP-glucuronosyltransferase (UGT), with a wider substrate specificity capable of glucuronidating 4-hydroxybiphenyl monoglucuronide to the diglucuronide.